SGHT - Sight Sciences, Inc. Stock Price, Fair Value and News

$3.57+0.21 (+6.25%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SGHT Price Action

Last 7 days

-0.3%

Last 30 days

-4.3%

Last 90 days

-46.7%

Trailing 12 Months

13.3%

SGHT RSI Chart

SGHT Valuation

Market Cap

181.2M

Price/Earnings (Trailing)

-3.6

Price/Sales (Trailing)

2.28

EV/EBITDA

-2.17

Price/Free Cashflow

-7

SGHT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SGHT Fundamentals

SGHT Revenue

Revenue (TTM)

79.5M

Rev. Growth (Yr)

0.74%

Rev. Growth (Qtr)

-5.68%

SGHT Earnings

Earnings (TTM)

-50.4M

Earnings Growth (Yr)

15.11%

Earnings Growth (Qtr)

10.24%

SGHT Profitability

EBT Margin

-63.04%

Return on Equity

-53.03%

Return on Assets

-35.06%

Free Cashflow Yield

-14.29%

SGHT Investor Care

Shares Dilution (1Y)

4.11%

Diluted EPS (TTM)

-1.02

SGHT Alerts

2 major insider buys and 1 major insider sales recently.
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	81.5M	79.4M	79.5M	0
2023	75.3M	81.5M	82.8M	81.1M
2022	55.2M	59.9M	65.5M	71.3M
2021	33.0M	38.3M	43.6M	49.0M
2020	0	0	0	27.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Sight Sciences, Inc.

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

CEO	Mr. Paul Badawi
WEBSITE	sightsciences.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	250

Sight Sciences, Inc. Frequently Asked Questions

What is the ticker symbol for Sight Sciences, Inc.? What does SGHT stand for in stocks?

SGHT is the stock ticker symbol of Sight Sciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sight Sciences, Inc. (SGHT)?

As of Fri Dec 20 2024, market cap of Sight Sciences, Inc. is 181.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGHT stock?

You can check SGHT's fair value in chart for subscribers.

Is Sight Sciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether SGHT is over valued or under valued. Whether Sight Sciences, Inc. is cheap or expensive depends on the assumptions which impact Sight Sciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGHT.

What is Sight Sciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, SGHT's PE ratio (Price to Earnings) is -3.6 and Price to Sales (PS) ratio is 2.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGHT PE ratio will change depending on the future growth rate expectations of investors.